Medtronic PLC $MDT Shares Sold by D.A. Davidson & CO.

D.A. Davidson & CO. lessened its position in shares of Medtronic PLC (NYSE:MDT - Free Report) by 7.7% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 197,008 shares of the medical technology company's stock after selling 16,474 shares during the quarter. D.A. Davidson & CO.'s holdings in Medtronic were worth $18,925,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. S.A. Mason LLC acquired a new position in shares of Medtronic during the 4th quarter worth approximately $104,000. Kestra Private Wealth Services LLC raised its position in shares of Medtronic by 3.6% during the 4th quarter. Kestra Private Wealth Services LLC now owns 113,218 shares of the medical technology company's stock worth $10,876,000 after purchasing an additional 3,918 shares during the last quarter. Scissortail Wealth Management LLC raised its position in shares of Medtronic by 1.9% during the 4th quarter. Scissortail Wealth Management LLC now owns 50,608 shares of the medical technology company's stock worth $4,861,000 after purchasing an additional 965 shares during the last quarter. Simon Quick Advisors LLC raised its position in shares of Medtronic by 0.9% during the 4th quarter. Simon Quick Advisors LLC now owns 48,703 shares of the medical technology company's stock worth $4,678,000 after purchasing an additional 453 shares during the last quarter. Finally, Facet Wealth Inc. acquired a new position in shares of Medtronic during the 4th quarter worth approximately $214,000. Institutional investors and hedge funds own 82.06% of the company's stock.

Key Medtronic News

Here are the key news stories impacting Medtronic this week:

• Positive Sentiment: Medtronic launched its Adaptive Deep Brain Stimulation (aDBS) system in India, expanding commercialization of an advanced Parkinson’s therapy into a large, fast‑growing market — a clear revenue/market‑share growth catalyst over time. Read More.
• Positive Sentiment: Analyst/commentary pieces argue investor expectations are low for MDT and position that downside is limited while upside exists if growth accelerates or adoption of new devices outperforms. This framing can support a re-rate if short‑term execution signals improve. Read More.
• Positive Sentiment: Medtronic won an FDA Breakthrough Device designation for the Sphere‑9 catheter and reported clinical milestones tied to Affera — regulatory and clinical progress that could accelerate product timelines in cardiac arrhythmia treatments. Read More.
• Neutral Sentiment: New pulsed‑field ablation (PFA) and other cardiac device data from HRS 2026 highlight competitive dynamics (Boston Scientific, Abbott, Medtronic). Data may drive medium‑term market‑share shifts but doesn’t immediately change revenue until adoption/clearance progresses. Read More.
• Neutral Sentiment: Market commentary (Kalkine) reviews valuation and near‑term catalysts; useful for investors assessing risk/reward but not a direct driver of price action. Read More.
• Negative Sentiment: Medtronic disclosed a cybersecurity breach in portions of its IT systems. Management says manufacturing, distribution and patient‑facing devices were not affected and the impact is not expected to be material, but the incident raises reputational, remediation‑cost and data‑security concerns that can pressure the stock until details and remediation outcomes are clear. Read More.

Medtronic Stock Down 0.5%

Shares of NYSE MDT opened at $82.89 on Tuesday. The company has a current ratio of 2.54, a quick ratio of 1.87 and a debt-to-equity ratio of 0.57. Medtronic PLC has a 12-month low of $79.93 and a 12-month high of $106.33. The stock has a fifty day moving average price of $89.44 and a 200 day moving average price of $95.12. The company has a market cap of $106.42 billion, a P/E ratio of 23.09, a P/E/G ratio of 2.16 and a beta of 0.75.

Medtronic (NYSE:MDT - Get Free Report) last issued its quarterly earnings data on Tuesday, February 17th. The medical technology company reported $1.36 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.34 by $0.02. Medtronic had a net margin of 13.00% and a return on equity of 14.82%. The company had revenue of $9.02 billion during the quarter, compared to the consensus estimate of $8.89 billion. During the same quarter last year, the company earned $1.38 earnings per share. Medtronic's revenue for the quarter was up 5.8% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. Research analysts anticipate that Medtronic PLC will post 5.57 EPS for the current fiscal year.

Medtronic Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Friday, April 17th. Shareholders of record on Friday, March 27th were given a $0.71 dividend. The ex-dividend date of this dividend was Friday, March 27th. This represents a $2.84 annualized dividend and a yield of 3.4%. Medtronic's dividend payout ratio (DPR) is 79.11%.

Analysts Set New Price Targets

Several research analysts recently weighed in on MDT shares. Evercore set a $106.00 target price on shares of Medtronic and gave the company an "outperform" rating in a research note on Thursday, April 9th. Barclays boosted their target price on shares of Medtronic from $118.00 to $120.00 and gave the company an "overweight" rating in a research note on Wednesday, April 1st. Mizuho cut their target price on shares of Medtronic from $125.00 to $120.00 and set an "outperform" rating for the company in a research note on Monday, April 13th. CICC Research started coverage on shares of Medtronic in a research note on Friday, January 30th. They issued an "outperform" rating for the company. Finally, Daiwa Securities Group cut their target price on shares of Medtronic from $117.00 to $115.00 and set a "buy" rating for the company in a research note on Friday, February 27th. Fifteen equities research analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to data from MarketBeat.com, Medtronic has an average rating of "Moderate Buy" and a consensus target price of $107.80.

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Skip Kiil sold 52,524 shares of the stock in a transaction that occurred on Thursday, February 19th. The shares were sold at an average price of $97.71, for a total value of $5,132,120.04. Following the completion of the sale, the executive vice president owned 32,768 shares of the company's stock, valued at $3,201,761.28. This trade represents a 61.58% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.26% of the stock is owned by company insiders.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic's offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).

Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic PLC (NYSE:MDT - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.